 |
274 Diseases |  |
1060 Trials |
|
1060 Trials |  |
12189 News |  |
| «12...167168169170171172173174175176177178179» |
- |||| Avastin (bevacizumab) / Roche
Trial completion, Combination therapy, Metastases: Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Jun 16, 2012
P2, N=51, Completed, Sponsor: North Central Cancer Treatment Group
Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche
Trial completion, Surgery, Metastases: Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Jun 16, 2012
P2, N=41, Completed, Sponsor: North Central Cancer Treatment Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| necuparanib (M 402) / J&J
New P1/2 trial, Combination therapy, Metastases: M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer (clinicaltrials.gov) - Jun 14, 2012
P1/2, N=180, Recruiting, Sponsor: Momenta Pharmaceuticals, Inc.
- albumin-bound paclitaxel / Generic mfg.
New P2 trial, Metastases: Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Jun 13, 2012
P2, N=29, Recruiting, Sponsor: University of Washington
- albumin-bound paclitaxel / Generic mfg.
Enrollment open, Metastases: Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Jun 13, 2012
P2, N=40, Recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Herceptin (trastuzumab) / Roche
Enrollment change, Combination therapy: Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane (clinicaltrials.gov) - May 12, 2012
P2, N=27, Completed, Sponsor: Emory University
Not yet recruiting --> Recruiting N=16 --> 27
- tigatuzumab (CS-1008) / Daiichi Sankyo
Enrollment closed, Metastases: Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer (clinicaltrials.gov) - May 7, 2012
P2, N=66, Active, not recruiting, Sponsor: University of Alabama at Birmingham
N=16 --> 27 Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
Enrollment closed: Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer (clinicaltrials.gov) - May 2, 2012
P1, N=24, Active, not recruiting, Sponsor: David O'Malley
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- carboplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg., sorafenib / Generic mfg.
Enrollment change, Metastases: A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma (clinicaltrials.gov) - May 1, 2012
P2, N=34, Completed, Sponsor: Mt. Sinai Medical Center, Miami
Recruiting --> Active, not recruiting N=43 --> 34
- || Perjeta (pertuzumab) / Roche
New P3 trial: Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) (clinicaltrials.gov) - Apr 22, 2012
P3, N=1200, Active, not recruiting, Sponsor: German Breast Group
- |||||||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P3 trial, Combination therapy, Metastases: PERUSE: A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer (clinicaltrials.gov) - Apr 3, 2012
P3, N=1500, Recruiting, Sponsor: Hoffmann-La Roche
- albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Enrollment change, Combination therapy, Metastases: Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine in Treating Patients With Advanced Metastatic Solid Tumors (clinicaltrials.gov) - Apr 1, 2012
P1, N=18, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
N=43 --> 34 N=25 --> 18
- Leukine (sargramostim) / Partner Therap
Enrollment change, Metastases: Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy (clinicaltrials.gov) - Mar 27, 2012
P2, N=21, Completed, Sponsor: University of Washington
N=25 --> 18 N=30 --> 21
- albumin-bound paclitaxel / Generic mfg.
New P2 trial, IO biomarker, Metastases: Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer (clinicaltrials.gov) - Mar 27, 2012
P2, N=29, Active, not recruiting, Sponsor: Washington University School of Medicine
- Leukine (sargramostim) / Partner Therap
Trial completion, Metastases: Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy (clinicaltrials.gov) - Mar 27, 2012
P2, N=21, Completed, Sponsor: University of Washington
N=30 --> 21 Active, not recruiting --> Completed
- ||||| albumin-bound paclitaxel / Generic mfg.
New P2 trial: Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer (clinicaltrials.gov) - Mar 26, 2012
P2, N=78, Active, not recruiting, Sponsor: Spanish Breast Cancer Research Group
- Avastin (bevacizumab) / Roche
Enrollment closed: Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel Bevacizumab for Primary Ovarian (clinicaltrials.gov) - Mar 16, 2012
P1, N=30, Active, not recruiting, Sponsor: Ritu Salani
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | albumin-bound paclitaxel / Generic mfg.
New P1/2 trial: Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma (clinicaltrials.gov) - Mar 14, 2012
P1/2, N=54, Recruiting, Sponsor: Washington University School of Medicine
- | erlotinib / Generic mfg., albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Combination therapy, Metastases: Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer (clinicaltrials.gov) - Mar 11, 2012
P1, N=19, Completed, Sponsor: OSI Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
New P2 trial, Metastases: A Phase II Study of Abraxane Gemcitabine Combination in Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Mar 8, 2012
P2, N=84, Recruiting, Sponsor: Fudan University
- albumin-bound paclitaxel / Generic mfg.
Enrollment closed, Metastases: Hepatic Arterial Infusion (HAI) of Abraxane (clinicaltrials.gov) - Feb 28, 2012
P1, N=56, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- albumin-bound paclitaxel / Generic mfg.
Enrollment change: Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis (clinicaltrials.gov) - Feb 20, 2012
P2, N=9, Terminated, Sponsor: Celgene Corporation
Recruiting --> Active, not recruiting N=20 --> 9
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial initiation date, Metastases: Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Feb 18, 2012
P2, N=40, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
N=20 --> 9 Initiation date: Sep 2011 --> Feb 2012
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Metastases: Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Feb 18, 2012
P2, N=40, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Initiation date: Sep 2011 --> Feb 2012 Not yet recruiting --> Recruiting
- carboplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Enrollment open, Surgery, Metastases: Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer (clinicaltrials.gov) - Feb 15, 2012
P2, N=45, Recruiting, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Caprelsa (vandetanib) / Sanofi
Enrollment closed, Combination therapy: Phase I Abraxane Weekly and Three Weekly Schedule With Vandetanib (clinicaltrials.gov) - Feb 13, 2012
P1, N=65, Active, not recruiting, Sponsor: University of Southern California
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
Enrollment closed, Metastases: Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Feb 13, 2012
P2, N=36, Active, not recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- carboplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Enrollment change, Metastases: Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Feb 2, 2012
P1, N=47, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
Recruiting --> Active, not recruiting N=39 --> 47
- carboplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Trial completion, Metastases: Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Feb 2, 2012
P1, N=47, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
N=39 --> 47 Active, not recruiting --> Completed
- carboplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
New P2 trial, Surgery, Metastases: Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer (clinicaltrials.gov) - Feb 1, 2012
P2, N=45, Recruiting, Sponsor: City of Hope Medical Center
- Avastin (bevacizumab) / Roche
Enrollment closed: Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer (clinicaltrials.gov) - Jan 31, 2012
P2, N=60, Active, not recruiting, Sponsor: William Sikov
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Zolinza (vorinostat) / Merck (MSD)
Biomarker, Enrollment closed: Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer (clinicaltrials.gov) - Jan 17, 2012
P2, N=74, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed: Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov) - Jan 16, 2012
P1, N=30, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| 5-fluorouracil / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Trial completion: Phase II Study of ABI-007 for Gastric Cancer (clinicaltrials.gov) - Jan 10, 2012
P2, N=56, Completed, Sponsor: Taiho Pharmaceutical Co., Ltd.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
Enrollment change, Metastases: Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer (clinicaltrials.gov) - Jan 9, 2012
P2, N=5, Completed, Sponsor: University of Pennsylvania
Active, not recruiting --> Completed N=37 --> 5
- Avastin (bevacizumab) / Roche
Trial completion, Metastases: Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer (clinicaltrials.gov) - Jan 9, 2012
P2, N=5, Completed, Sponsor: University of Pennsylvania
N=37 --> 5 Recruiting --> Completed
- hydroxychloroquine / Generic mfg., albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
New P1/2 trial, Combination therapy: A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer (clinicaltrials.gov) - Jan 8, 2012
P1/2, N=40, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
- Herceptin (trastuzumab) / Roche
Trial completion, Combination therapy: Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane (clinicaltrials.gov) - Dec 28, 2011
P2, N=27, Completed, Sponsor: Emory University
Recruiting --> Completed Recruiting --> Completed
- Avastin (bevacizumab) / Roche
Enrollment open, Metastases: Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies (clinicaltrials.gov) - Dec 20, 2011
P1, N=120, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed Active, not recruiting --> Recruiting
- carboplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
New P2 trial, Metastases: Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer (clinicaltrials.gov) - Dec 13, 2011
P2, N=21, Not yet recruiting, Sponsor: First People's Hospital of Hangzhou
- Mifeprex (mifepristone) / Danco Laboratories
New P1 trial, Metastases: Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer (clinicaltrials.gov) - Dec 13, 2011
P1, N=32, Active, not recruiting, Sponsor: University of Chicago
- |||||||||| Onzeald (etirinotecan pegol) / Nektar Therap
New P3 trial, Metastases: The BEACON Study (Breast Cancer Outcomes With NKTR-102) (clinicaltrials.gov) - Dec 12, 2011
P3, N=840, Active, not recruiting, Sponsor: Nektar Therapeutics
- | New P2 trial, Metastases: Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer (clinicaltrials.gov) - Dec 6, 2011
P2, N=61, Recruiting, Sponsor: Pancreatic Cancer Research Team
- ||| Nerlynx (neratinib) / Puma
Enrollment closed, Metastases: NEFERTT: Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer (clinicaltrials.gov) - Dec 6, 2011
P2, N=480, Active, not recruiting, Sponsor: Puma Biotechnology, Inc.
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- | carboplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Enrollment closed, Metastases: Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer (clinicaltrials.gov) - Dec 1, 2011
P2, N=33, Active, not recruiting, Sponsor: University of Michigan Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Surgery: RTOG-0617: High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Nov 24, 2011
P3, N=500, Active, not recruiting, Sponsor: Radiation Therapy Oncology Group
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Onureg (azacitidine oral) / BMS
New P1 trial, Combination therapy: A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Nov 21, 2011
P1, N=160, Recruiting, Sponsor: Celgene Corporation
- cisplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Trial completion, Metastases: A Combination of Abraxane and Cisplatin in Metastatic Breast Cancer (clinicaltrials.gov) - Nov 20, 2011
P2, N=73, Completed, Sponsor: Fudan University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- carboplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Trial termination: Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC (clinicaltrials.gov) - Nov 16, 2011
P1/2, N=13, Terminated, Sponsor: Vanderbilt-Ingram Cancer Center
Recruiting --> Terminated; Ph I completed. Funding became unavailable causing Ph II to cease after two patients were enrolled.
- carboplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Enrollment change: Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC (clinicaltrials.gov) - Nov 16, 2011
P1/2, N=13, Terminated, Sponsor: Vanderbilt-Ingram Cancer Center
Funding became unavailable causing Ph II to cease after two patients were enrolled. N=95 --> 13